secwatch / observer
8-K filed May 15, 2024, 7:59 PM ET ticker VRTX CIK 0000875320
other material confidence high sentiment neutral materiality 0.15

Vertex Pharmaceuticals Shareholders Elect Directors and Approve Proposals at Annual Meeting

VERTEX PHARMACEUTICALS INC / MA

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Reshma Kewalramani as director at the 2024-05-15 meeting.

Proposal
director election
Outcome
passed
Meeting
2024-05-15
Exact text from the filing
nual meeting of shareholders to be held in 2025: For Against Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Bruce Sachs as director at the 2024-05-15 meeting.

Proposal
director election
Outcome
passed
Meeting
2024-05-15
Exact text from the filing
,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Jeffrey Leiden as director at the 2024-05-15 meeting.

Proposal
director election
Outcome
passed
Meeting
2024-05-15
Exact text from the filing
08,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Alan Garber as director at the 2024-05-15 meeting.

Proposal
director election
Outcome
passed
Meeting
2024-05-15
Exact text from the filing
as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2025: For Against Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Jennifer Schneider as director at the 2024-05-15 meeting.

Proposal
director election
Outcome
passed
Meeting
2024-05-15
Exact text from the filing
6 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Lloyd Carney as director at the 2024-05-15 meeting.

Proposal
director election
Outcome
passed
Meeting
2024-05-15
Exact text from the filing
neider, Nancy Thornberry and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2025: For Against Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider, Nancy Thornberry and Suketu Upadhyay as directors at the 2024-05-15 meeting.

Proposal
director election
Outcome
passed
Meeting
2024-05-15
Exact text from the filing
Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider, Nancy Thornberry and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2025: For Against Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for 2024 at the 2024-05-15 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2024-05-15
Exact text from the filing
Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024: For Against Abstain Non-Votes 229,460,523 3,987,619 290,126 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Diana McKenzie as director at the 2024-05-15 meeting.

Proposal
director election
Outcome
passed
Meeting
2024-05-15
Exact text from the filing
,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Michel Lagarde as director at the 2024-05-15 meeting.

Proposal
director election
Outcome
passed
Meeting
2024-05-15
Exact text from the filing
gainst Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Shareholder proposal regarding a special shareholder meeting improvement at the 2024-05-15 meeting.

Outcome
passed
Meeting
2024-05-15
Exact text from the filing
Based upon the following votes, the shareholders approved a shareholder proposal regarding a special shareholder meeting improvement: For Against Abstain Non-Votes 160,438,357 61,494,550 265,212 11,540,149
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Advisory approval of 2023 compensation program for named executive officers at the 2024-05-15 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2024-05-15
Exact text from the filing
Based upon the following votes, the shareholders approved, on an advisory basis, the 2023 compensation program for the Company's named executive officers: For Against Abstain Non-Votes 202,098,575 19,223,784 875,760 11,540,149
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders rejected Shareholder proposal regarding a report on racial and gender pay gaps at the 2024-05-15 meeting.

Outcome
failed
Meeting
2024-05-15
Exact text from the filing
Based upon the following votes, the shareholders did not approve a shareholder proposal regarding a report on racial and gender pay gaps: For Against Abstain Non-Votes 63,865,687 157,637,997 694,435 11,540,149
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Nancy Thornberry as director at the 2024-05-15 meeting.

Proposal
director election
Outcome
passed
Meeting
2024-05-15
Exact text from the filing
186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Suketu Upadhyay as director at the 2024-05-15 meeting.

Proposal
director election
Outcome
passed
Meeting
2024-05-15
Exact text from the filing
178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No. 2 : Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024: For Against Abstain Non-Votes 229,460,523 3,987,619 290,126 0 Proposal No.
View on SEC.gov

23 shareholder votes filed in the last 30 days. Browse all shareholder votes →

VERTEX PHARMACEUTICALS INC / MA filing history →

Source: SEC EDGAR
accession 0000875320-24-000142
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.